Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

Question for you.
Are you familiar with SIRS Systemic Inflammatory Response Syndrome? Since Brilacidin is broad spectrum, and has anti-inflammatory properties and is less likely contribute to antibiotic resistance, could you see it becoming the go-to for this indication?


"Management of the critically ill patient with sepsis is ideally undertaken in the intensive care unit. Early recognition of sepsis is important in the management of the condition allowing earlier intervention. The aim of initial resuscitation and supportive therapies is to maintain organ perfusion and oxygenation. Hypoxaemia should be treated with increased inspired oxygen concentrations and monitored with pulse oximetry and regular blood gas estimations. Mechanical ventilation is often required to support failing respiratory function and reduce the work of breathing due to non-compliant lungs. Cardiovascular support in the form of fluids, inotropes and vasoconstrictors are instigated and their use may be guided with a pulmonary artery catheter. Microbiological samples should be collected including blood cultures, urine and sputum to aid identification of responsible pathogens. Antibiotic therapy is initiated on an empirical basis with broad-spectrum antibiotics; this is then tailored to implicated organisms as microbiological results become available. Failure to instigate appropriate antibiotic therapy promptly is associated with increased mortality."